Hero

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Celyad Announces Third Quarter 2018 Business Update

Celyad Announces Third Quarter 2018 Business Update

Discover all news

Carousel

Social Feed

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting… https://t.co/17vOoEBDKZ

2 weeks ago

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting… https://t.co/17vOoEBDKZ

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candida… https://t.co/33yKfAR8mX

2 weeks ago

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candida… https://t.co/33yKfAR8mX

RT @EdisonHealth: .@CelyadSA: Really encouraging solid #cancer data in November with important update on #AML on December 3 at ASH. #Alloge…

3 weeks ago

RT @EdisonHealth: .@CelyadSA: Really encouraging solid #cancer data in November with important update on #AML on December 3 at ASH. #Alloge…

Celyad Announces Third Quarter 2018 Business Update. Read the full Press Release: https://t.co/H1TqLc0YHf https://t.co/lX122pqJ53

3 weeks ago

Celyad Announces Third Quarter 2018 Business Update. Read the full Press Release: https://t.co/H1TqLc0YHf https://t.co/lX122pqJ53

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting… https://t.co/17vOoEBDKZ

2 weeks ago

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting… https://t.co/17vOoEBDKZ

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candida… https://t.co/33yKfAR8mX

2 weeks ago

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candida… https://t.co/33yKfAR8mX

RT @EdisonHealth: .@CelyadSA: Really encouraging solid #cancer data in November with important update on #AML on December 3 at ASH. #Alloge…

3 weeks ago

RT @EdisonHealth: .@CelyadSA: Really encouraging solid #cancer data in November with important update on #AML on December 3 at ASH. #Alloge…

Celyad Announces Third Quarter 2018 Business Update. Read the full Press Release: https://t.co/H1TqLc0YHf https://t.co/lX122pqJ53

3 weeks ago

Celyad Announces Third Quarter 2018 Business Update. Read the full Press Release: https://t.co/H1TqLc0YHf https://t.co/lX122pqJ53